TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Accesswire
*TAMPA, FL* *and* *SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / *TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage..